查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984174

多癌種篩檢市場：按檢測類型、癌症類型、技術、支付方式、應用和最終用戶分類－2026-2032年全球市場預測

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，多癌篩檢市場價值將達到 6.3087 億美元，到 2026 年將成長至 8.2284 億美元，到 2032 年將達到 43.7542 億美元，年複合成長率為 31.87%。

主要市場統計數據
基準年 2025 6.3087億美元
預計年份：2026年 8.2284億美元
預測年份 2032 4,375,420,000 美元
複合年成長率 (%) 31.87%

本文全面概述了多癌種篩檢技術的進步如何改變臨床實踐、研究重點以及診斷和護理路徑中的相關人員合作。

分子生物學、生物資訊學和檢體採集技術的進步正推動多篩檢領域從充滿前景的實驗性探索走向臨床和研究領域的實際應用。新的診斷方法透過擴大微創檢體的組織範圍，重塑了檢測模式，從而再形成了臨床工作流程和病患照護路徑。因此，參與診斷開發、醫療服務和政策制定的相關人員正在重新評估早期檢測、長期監測和循證醫學證據生成等方面的優先事項，以支持臨床應用。

技術、臨床和支付方的進步如何重新定義多癌種篩檢創新領域的發展重點和部署路徑？

技術變革、數據整合以及報銷理念的轉變正在推動多癌症種篩檢領域發生一系列顛覆性變化。在技​​術層面，液態生物檢體、高通量定序和多重檢測的創新正在拓展可檢測分析物的範圍，並降低非侵入性取樣的門檻。這些技術進步正在促成先進生物資訊流程的建立，從而提高訊號檢測的準確性並降低假陽性噪聲，最終產生更多臨床實用結果。

該評估旨在評估美國關稅政策的變化如何影響診斷產業相關人員在供應鏈韌性、籌資策略和製造本地化方面的決策。

關稅政策和貿易措施的變化將對用於多癌種篩檢的試劑、儀器和客製化檢測組件的全球供應鏈產生重大影響。在美國，關稅體系的變化正在影響定序試劑、質譜耗材和專用硬體等關鍵投入品的到貨成本，進而影響檢查室和診斷開發人員的採購偏好。這些成本壓力促使他們更加關注國內採購、策略供應商合作以及庫存管理，以確保檢測服務的連續性。

透過綜合細分分析，揭示測試類型、目標癌症、技術、支付來源、應用和最終用戶如何共同影響其採用和臨床效用。

細分分析突顯了技術方法、臨床標靶、支付模式和最終用戶群的多樣性，這些因素共同塑造了多癌種篩檢的路徑。根據檢測類型，目前的檢測方案涵蓋了從針對特定基因組區域的基因panel檢測到經認證實驗室提供的客製化實驗室自建檢測（LDT），甚至包括液態生物檢體——一種利用循環血液中分析物質的微創採樣方法。根據癌症類型，目前的篩檢涵蓋了已建立的靶點，例如乳癌和結直腸癌；骨髓惡性腫瘤，例如白血病；高負擔適應症，例如肺癌；廣泛且特異性的多器官癌症檢測模式；以及器官特異性靶點，例如前列腺癌。

區域比較分析突顯了法律規範、支付模式和醫療保健基礎設施如何在世界各地造成不同的採用路徑。

區域趨勢對多篩檢計畫的實施路徑、監管預期和支付方參與度有顯著影響。在美洲，成熟的醫療基礎設施、活躍的私人保險市場和強大的轉化研究網路，為商業性試點計畫和經營模式的快速推進創造了有利環境。同時，監管監督和報銷討論的重點在於證明其臨床效用並將其整合到臨床流程中。在歐洲、中東和非洲，監管協調的努力、多樣化的報銷環境和不同的醫療服務體系，都要求採用適應性強的循證策略、本地化的衛生經濟學模型以及有針對性的相關人員參與，以確保計畫的成功實施。

協作、平台差異化和循證定位如何塑造診斷開發公司和檢測實驗室的競爭策略和商業化路徑。

多癌種篩檢領域的競爭格局呈現出多元化的特點，既有成熟的診斷公司，也有專業的臨床實驗室，還有追求差異化科學方法的敏捷生物技術Start-Ups。許多成熟公司正在拓展檢測項目組合，並加強與臨床網路的合作，以檢驗更廣泛篩檢應用的適用性。同時，專業實驗室正在整合工作流程並建立認證體系，以支援內部自建檢測（LDT）的快速迭代。Start-Ups傾向於專注於獨特的生物標記平台、創新的生物資訊技術或檢體收集方面的創新，以應對靈敏度、特異性或易用性方面的特定挑戰。

為開發人員、測試實驗室和醫療保健系統提供切實可行的、基於證據的建議，以加速多癌種篩檢的可靠實施和營運彈性。

產業領導者可以透過以下方式加速負責任地推廣多癌症種篩檢：將產品開發與明確的臨床應用案例結合，優先考慮分析的嚴謹性，並儘早與保險公司和醫療服務提供者合作。首先，制定有針對性的臨床路徑，明確如何處理陽性篩檢結果、必要的確診步驟以及如何協調後續照護。清晰界定後續行動有助於增強臨床效用的論證。其次，投資於不同檢體類型和人群的分析有效性和可重複性，以減少變異性並增強臨床醫生的信心。第三，儘早與保險公司展開對話，建構反映實際照護路徑和病人歷程的衛生經濟模型，為報銷談判奠定基礎。

我們採用嚴格的混合方法研究框架檢驗了我們在多篩檢的發現，該框架結合了專家訪談、同行評審的證據、監管檢驗和資料三角驗證。

本研究途徑結合了多方面的證據收集、專家檢驗和迭代整合，以得出平衡且可操作的見解。主要研究包括對臨床醫生、檢查室管理人員、衛生經濟學家和保險公司進行結構化訪談，以了解臨床實踐中的營運限制、證據預期和決策因素。次要研究則利用同行評審文獻、臨床試驗註冊數據、監管申報文件以及衛生技術評估機構發布的公共指南，揭示技術能力和政策趨勢。資料三角測量法用於調整不同觀點，並識別不同資訊來源中的一致訊號。

總之，綜合分析強調，證據的一致性、操作準備以及多方相關人員之間的合作是負責任地實施多癌症種篩檢的先決條件。

多癌種篩檢正處於轉折點，技術成熟度、臨床整合需求以及支付方觀點的轉變共同塑造其未來的發展方向。儘管技術進步使得更廣泛、更微創的檢測成為可能，但永續推廣應用仍需有可驗證的臨床路徑、可互通的報告系統以及一致的報銷機制。相關人員致力於明確應用場景定義、在不同人群中進行充分檢驗並與醫療網路開展務實合作的利益相關者，將更有能力將創新轉化為可衡量的臨床獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測類型分類的多癌症種篩檢市場

  • 基因檢測
  • 實驗室開發的測試
  • 液態生物檢體

第9章：按癌症類型分類的多癌症種篩檢市場

  • 乳癌
  • 結腸癌
  • 白血病
  • 肺癌
  • 特異性多重器官癌
  • 攝護腺癌

第10章：多癌種篩檢市場：依技術分類

  • 質譜分析
  • 微陣列
  • 次世代定序
  • 聚合酵素鏈鎖反應

第11章：按支付方式分類的多癌症種篩檢市場

  • 政府補貼
  • 自費
  • 私人醫療保險

第12章：多癌種篩檢市場：依應用領域分類

  • 診斷篩檢
    • 早期檢測
    • 風險評估
  • 預後
    • 病患監測
    • 治療方法方案
    • 治療效果評估
  • 出於研究目的
    • 生物標記的發現
    • 基因研究

第13章：多癌種篩檢市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院
  • 研究機構
  • 專科診所

第14章：多重癌症篩檢市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：多癌種篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：多重癌症篩檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國多癌症種篩檢市場

第18章：中國多癌症種篩檢市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market was valued at USD 630.87 million in 2025 and is projected to grow to USD 822.84 million in 2026, with a CAGR of 31.87%, reaching USD 4,375.42 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 630.87 million
Estimated Year [2026] USD 822.84 million
Forecast Year [2032] USD 4,375.42 million
CAGR (%) 31.87%

A compelling overview of how multicancer screening advances are shifting clinical practice, research priorities, and stakeholder collaboration across diagnostics and care pathways

The field of multicancer screening is evolving from experimental promise to pragmatic integration within clinical and research settings, driven by converging advances in molecular biology, bioinformatics, and sample collection technologies. Emerging diagnostic modalities are reframing detection paradigms by offering broader tissue coverage from minimally invasive samples, thereby reshaping clinical workflows and patient pathways. As a result, stakeholders across diagnostics development, healthcare delivery, and policy are reevaluating priorities around early detection, longitudinal monitoring, and evidence generation to sustain clinical adoption.

Clinical laboratories and developers are responding to both scientific and operational pressures: they must balance analytical sensitivity and specificity with throughput, cost, and regulatory compliance. Concurrently, payers and health systems are seeking clearer proof of clinical utility and actionable pathways to integrate positive findings into care. In this environment, translational research and pragmatic trials are emerging as critical bridges between biomarker discovery and routine use, helping to define appropriate use cases, referral networks, and pathway economics that enable responsible scale-up. Consequently, organizations that invest now in robust clinical validation, interoperability, and stakeholder alignment stand to accelerate credible adoption and long-term impact.

How converging technological, clinical, and payer evolutions are redefining development priorities and adoption pathways in multicancer screening innovation

Transformations in technology, data integration, and reimbursement thinking are producing a set of disruptive shifts across the multicancer screening landscape. On the technology front, innovations in liquid biopsy, high-throughput sequencing, and multiplexed assays are expanding the range of detectable analytes and lowering the barrier to noninvasive sampling. These technical gains are accompanied by enhanced bioinformatic pipelines that improve signal detection and reduce false positive noise, enabling more clinically actionable outputs.

At the systems level, there is a move toward integrated care models that link screening results to standardized diagnostic follow-up and treatment pathways. This integration is facilitated by interoperable data standards and electronic health record connectivity that allow screening outcomes to trigger timely clinical responses. Simultaneously, payer discussions are evolving from unitary reimbursement for single-disease tests toward value frameworks that consider longitudinal benefit and downstream care coordination. As a result, stakeholders are recalibrating product development strategies, clinical evidence plans, and commercialization roadmaps to align with these transformative shifts and to secure sustainable clinical and commercial pathways.

Assessing how shifting US tariff policies are influencing supply chain resilience, procurement strategies, and manufacturing localization decisions for diagnostic stakeholders

Tariff policy changes and trade measures can exert meaningful influence on global supply chains for reagents, instruments, and bespoke assay components used in multicancer screening. In the United States, shifts in tariff regimes affect the landed cost of critical inputs such as sequencing reagents, mass spectrometry consumables, and specialized hardware, which in turn influence procurement preferences among laboratories and diagnostic developers. These cost pressures encourage greater attention to domestic sourcing, strategic supplier partnerships, and inventory management practices to maintain continuity of testing services.

Beyond cost considerations, tariffs can accelerate strategic decisions about manufacturing footprint and localization of critical production steps, prompting firms to evaluate regionalized supply chains and nearshoring options. For some organizations, this translates into increased investments in domestic contract manufacturing, secondary sourcing contracts, and supplier qualification programs to mitigate exposure. In parallel, procurement teams and laboratory operators are intensifying scenario planning to absorb short-term pricing volatility while preserving assay performance and regulatory compliance. Ultimately, tariff dynamics serve as both an operational stress test and a catalyst for supply chain resilience strategies that align with long-term clinical service objectives.

Integrated segmentation insights that reveal how test type, cancer target, technology, payment source, application, and end user collectively shape adoption and clinical utility

Segmentation analysis highlights the diversity of technological approaches, clinical targets, payment models, and end users that shape multicancer screening pathways. Based on test type, contemporary offerings range from gene panel approaches that target defined genomic regions to laboratory developed tests that are tailored within certified labs, and to liquid biopsy methods that leverage circulating analytes for minimally invasive sampling. Based on cancer type, the screening landscape spans established targets such as breast cancer and colorectal cancer, hematologic malignancies like leukemia, high-burden indications such as lung cancer, broad non-specific multi-organ cancer detection paradigms, and organ-specific targets like prostate cancer.

Based on technology, core platforms include mass spectrometry for proteomic signatures, microarray approaches for targeted genomic profiling, next-generation sequencing for comprehensive genomic and epigenomic interrogation, and polymerase chain reaction techniques for focused, high-sensitivity detection. Based on payment source, funding and access pathways vary with government subsidies that support public health initiatives, out-of-pocket payment for direct-to-consumer or elective services, and private health insurance that evaluates clinical utility and cost-effectiveness criteria. Based on application, offerings cover diagnostic screening for early detection and risk assessment, prognostic uses such as patient monitoring, therapy selection, and treatment efficacy assessment, and research applications including biomarker discovery and genetic research. Based on end user, deployment spans ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, each with distinct operational constraints, specimen logistics, and reporting requirements. Together, these segmentation lenses underscore the need for tailored evidence generation, commercial strategies, and implementation pathways that align with the intended use case and stakeholder expectations.

Comparative regional insights highlighting how regulatory frameworks, payer models, and healthcare infrastructure drive differentiated adoption pathways across global regions

Regional dynamics exert a pronounced influence on adoption pathways, regulatory expectations, and payer engagement for multicancer screening programs. In the Americas, mature healthcare infrastructures, active private payer markets, and strong translational research networks create an environment where commercial pilots and commercial models can advance rapidly, while regulatory oversight and reimbursement discussions focus on demonstrating clinical utility and care pathway integration. In Europe, Middle East & Africa, regulatory harmonization initiatives, variable reimbursement environments, and diverse healthcare delivery settings require adaptable evidence strategies, localized health economic models, and targeted stakeholder engagement to secure uptake.

In the Asia-Pacific region, rapid investments in sequencing capacity, growing public health screening initiatives, and expanding clinical trial activity are driving a dynamic landscape where both domestic innovators and global players pursue partnership models. Each region presents distinct operational considerations: supply chain logistics and laboratory capacity differ across geographies, payer frameworks range from public program-driven funding to mixed private-public arrangements, and clinician awareness and care pathways vary by local practice patterns. Consequently, commercial and clinical strategies must be regionally calibrated to address regulatory nuance, reimbursement pathways, and operational readiness while leveraging local research collaborations to accelerate evidence generation.

How collaboration, platform differentiation, and evidence-driven positioning are shaping competitive strategies and commercial pathways among diagnostic developers and laboratories

Competitive dynamics in the multicancer screening arena are characterized by a mix of established diagnostic manufacturers, specialized clinical laboratories, and nimble biotechnology startups pursuing differentiated scientific approaches. Many established players are expanding assay portfolios and forging partnerships with clinical networks to validate broader screening applications, while specialized laboratories are refining workflow integration and accreditation to support laboratory-developed tests with rapid iteration. Startups often focus on unique biomarker platforms, novel bioinformatics, or sample collection innovations that address specific gaps in sensitivity, specificity, or usability.

Strategic activity increasingly centers on collaboration: partnerships between technology providers and large laboratory networks enable access to diverse clinical specimens and pragmatic validation pathways, while alliances with academic centers facilitate translational studies and clinical utility evidence. In addition, contract development and manufacturing relationships help firms scale assay production, and collaborations with health systems support pilot implementations that test real-world clinical pathways. Across these dynamics, robustness of evidence, regulatory clarity, and the ability to integrate into clinical workflows remain primary differentiators that influence adoption trajectories and commercial positioning.

Practical, evidence-focused recommendations for developers, laboratories, and health systems to accelerate credible adoption and operational resilience in multicancer screening

Industry leaders can accelerate responsible adoption of multicancer screening by aligning product development with clear clinical use cases, prioritizing analytic rigor, and engaging early with payers and providers. First, define targeted clinical pathways that specify how a positive screening result will be triaged, what confirmatory diagnostics are required, and how follow-up care will be coordinated; clarity on downstream actions strengthens clinical utility arguments. Second, invest in analytical validation and reproducibility across diverse specimen types and demographic cohorts to reduce variability and build clinician confidence. Third, initiate payer dialogues early and develop health economic models that reflect realistic care pathways and patient journeys to inform reimbursement negotiations.

Operationally, leaders should pursue supply chain diversification and quality-controlled manufacturing to mitigate tariff and logistics risks while ensuring consistent test availability. In parallel, prioritize interoperable reporting formats and EHR integration to facilitate clinical decision support and reduce friction in provider workflows. From a commercialization perspective, pilot programs with integrated care partners, accompanied by pragmatic outcome measurement, provide actionable evidence that accelerates adoption. Finally, cultivate transparent communication with regulators and clinical societies to align on evidence thresholds and appropriate use cases, enabling scalable and clinically responsible deployment.

A rigorous mixed-methods research framework combining expert interviews, peer-reviewed evidence, regulatory review, and data triangulation to validate multicancer screening insights

The research approach combined multi-source evidence collection, expert validation, and iterative synthesis to produce balanced, actionable insights. Primary research included structured interviews with clinicians, laboratory directors, health economists, and payers to capture operational constraints, evidence expectations, and decision drivers across clinical settings. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory filings, and publicly available guidance from health technology assessment bodies to map technological capabilities and policy trends. Data triangulation was used to reconcile differing perspectives and to identify consistent signals across sources.

Analytical rigor was ensured by cross-checking technical claims against independent validation studies and by assessing operational feasibility through conversations with laboratory operators and supply chain experts. Key limitations and evidence gaps were explicitly characterized to inform future research priorities. Throughout the methodology, ethical considerations and data privacy practices guided the handling of any proprietary or patient-level information, and quality assurance steps were applied to maintain accuracy and credibility in the synthesis of findings.

Concluding synthesis emphasizing evidence alignment, operational readiness, and multi-stakeholder collaboration as prerequisites for responsible multicancer screening adoption

Multicancer screening is at an inflection point where technical maturity, clinical integration needs, and evolving payer perspectives converge to shape near-term trajectories. While technological advances are enabling broader and less invasive detection capabilities, sustainable adoption depends on demonstrable clinical pathways, interoperable reporting, and aligned reimbursement approaches. Stakeholders that pursue clear use case definition, robust validation across diverse cohorts, and pragmatic collaborations with care networks will be best positioned to translate innovation into measurable clinical benefit.

Looking ahead, the focus will be on closing evidence gaps around clinical utility, refining operational models to support scalable testing, and building resilient supply chains that accommodate changing trade and procurement landscapes. By emphasizing transparency in performance, fostering multi-stakeholder engagement, and investing in interoperable systems, the field can progress toward screening programs that deliver earlier detection, more personalized care, and improved outcomes for patients while ensuring sustainable implementation within health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multicancer Screening Market, by Test Type

  • 8.1. Gene Panel
  • 8.2. Laboratory Developed Test
  • 8.3. Liquid Biopsy

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Leukemia
  • 9.4. Lung Cancer
  • 9.5. Non-Specific Multi-Organ Cancer
  • 9.6. Prostate Cancer

10. Multicancer Screening Market, by Technology

  • 10.1. Mass Spectrometry
  • 10.2. Microarray
  • 10.3. Next - Generation Sequencing
  • 10.4. Polymerase Chain Reaction

11. Multicancer Screening Market, by Payment Source

  • 11.1. Government Subsidies
  • 11.2. Out-of-Pocket Payment
  • 11.3. Private Health Insurance

12. Multicancer Screening Market, by Application

  • 12.1. Diagnostic Screening
    • 12.1.1. Early Detection
    • 12.1.2. Risk Assessment
  • 12.2. Prognostics
    • 12.2.1. Patient Monitoring
    • 12.2.2. Therapy Selection
    • 12.2.3. Treatment Efficacy Assessment
  • 12.3. Research Applications
    • 12.3.1. Biomarker Discovery
    • 12.3.2. Genetic Research

13. Multicancer Screening Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Diagnostic Centers
  • 13.3. Hospitals
  • 13.4. Research Institutions
  • 13.5. Specialty Clinics

14. Multicancer Screening Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Multicancer Screening Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Multicancer Screening Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Multicancer Screening Market

18. China Multicancer Screening Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ANPAC Bio-Medical Science Co., Ltd.
  • 19.6. Burning Rock Biotech Limited
  • 19.7. Caris Life Sciences
  • 19.8. Coyne Medical Ltd.
  • 19.9. Delfi Diagnostics, Inc.
  • 19.10. Elypta AB
  • 19.11. EpiCypher, Inc.
  • 19.12. Epigenomics AG
  • 19.13. Exact Sciences Corporation
  • 19.14. Foundation Medicine, Inc.
  • 19.15. Freenome Holdings, Inc.
  • 19.16. Fulgent Genetics, Inc.
  • 19.17. Gene Solutions
  • 19.18. Grail, LLC by Illumina, Inc.
  • 19.19. Guangzhou AnchorDx Medical Co., Ltd.
  • 19.20. Guardant Health, Inc.
  • 19.21. Invitae Corporation
  • 19.22. Laboratory Corporation of America Holdings
  • 19.23. Lucence Health Inc.
  • 19.24. Micronoma, Inc.
  • 19.25. MiRXES Pte Ltd.
  • 19.26. Myriad Genetics, Inc.
  • 19.27. Natera, Inc.
  • 19.28. Naveris, Inc.
  • 19.29. NeoGenomics Laboratories
  • 19.30. OneTest
  • 19.31. Siemens Healthineers AG
  • 19.32. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)